News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review, page-14

Let's just say I personally would be keeping this as a small position in a portfolio.

Also, on @jetrodder's comments about the eventual long lasting income streams (should they ever eventuate), what I keep asking myself is:

How much competition are each of those streams going to face (it is not just ACR that is attracted to the "new era of generics") and does ACR have sufficient competitive muscle to hold its own?

I don't know the answer to these questions, & frankly I'm quite an ignoramus in this sector. I was attracted by what I perceived was a very unloved former high flyer, which had no current revenues (of any significance), but substantial cash (at the time) & residual intangible capital (IP, commercial relationships, operational know how etc). I took the punt because I felt that the negativity was driving the price low enough relative to the potential value, that it may swing the odds in my favor despite my lack of knowledge. But make no mistake, it was a punt.